Can brain scans predict radiation success? new trial aims to find out
NCT ID NCT04197297
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether CT and MRI scans can act as biomarkers to predict how patients with brain metastases respond to radiation therapy. About 90 adults with brain metastases who are scheduled for radiation will get scans before and after treatment. The goal is to validate imaging biomarkers that could one day help guide personalized treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors personalize radiation treatment for brain metastasis patients based on imaging biomarkers.
- What could go wrong
- This is an early-phase trial with only 90 participants, so results may not apply to all patients. The study focuses on measuring biomarkers, not on testing a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2021
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases) * At least one index lesion with diameter \> 1cm and without imaging evidence of hemorrhage * Patients age \> 18 years of age * Patients planned for RT to brain metastases * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Previous Whole Brain Radiotherapy * Previous radiosurgery to the index lesion * Individuals unable to undergo contrasted MRI for whatever reason
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Health Network
RECRUITINGToronto, Ontario, L4W4C2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single day of brain radiation match five days?
- Can doctors watch brain metastases instead of zapping them?
- Starving brain tumors of blood before surgery
- Tiny gadolinium particles aim to make brain radiation hit harder
- A sharper MRI could reveal radiation sensitivity of brain tumors
- Expert tumor board may extend survival in brain metastases